Compare Quantumscape Corp (QS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Twist Bioscience Corp — how do they compare? Quantumscape Corp trades at $4.57 (market cap $2.82B), while Twist Bioscience Corp trades at $159.86 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 3.6× Quantumscape Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Twist Bioscience Corp for 27 Days on average.
| QS | TWST | |
|---|---|---|
Market Cap | $2.82B | $10.08B |
Volume | 21,878,246 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $205.00 |
52-Week Low | $4.52 | $25.45 |
Typical Hold Time | 37 Days | 27 Days |
Enterprise Value | $2.03B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.52, down 2.8% on the day, reflecting ongoing investor skepticism about the solid-state battery developer's path to commercialization. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamental challenges persist with zero revenue, negative EBITDA of -$358.25M (2025), and consecutive quarterly losses. Recent news highlights commercialization delays and insider selling, though the company continues ramping pilot production lines for automotive and new market applications.
The outlook remains high-risk with commercialization not expected until 2029, creating significant execution and competitive threats. While the consensus price target of $10.35 suggests potential upside from current levels, analyst sentiment is cautious with 73% hold ratings. Investment opportunity exists only for speculative investors comfortable with pre-revenue developmental stage risks and extended timelines to profitability.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
